Table 1.
Summary of TCB‐2 induced alterations to Cv of ISI.
| Drug treatment | n | Cv of ISI | |||||
|---|---|---|---|---|---|---|---|
| Mean (whole trace) | SD | Mean (0–30 sec) | SD | Mean (30–60 sec) | SD | ||
| Control | 7 | 0.203 | 0.056 | 0.208 | 0.064 | 0.165 | 0.066 |
| TCB‐2 | 5 | 0.282 | 0.132 | 0.216 | 0.081 | 0.288 | 0.174 |
| TCB‐2 + bicuculline + DNQX + ketanserin | 5 | 0.230 | 0.090 | 0.193 | 0.064 | 0.206 | 0.106 |
| TCB‐2 + DNQX | 4 | 0.206 | 0.356 | 0.202 | 0.032 | 0.105 | 0.040 |
| TCB‐2 + bicuculline | 5 | 0.463 | 0.263 | 0.367 | 0.187 | 0.470 | 0.338 |
| TCB‐2 + DNQX + bicuculline | 7 | 0.617 | 0.207 | 0.461 | 0.212 | 0.686 | 0.214 |
| TCB‐2 + DNQX + gabazine | 7 | 0.622 | 0.28 | 0.401 | 0.246 | 0.772 | 0.390 |
Whole trace (60 sec), 0–30 sec, and 30–60 sec Cv of ISI for all drug combinations used in this study. Statistical comparisons between groups are depicted in fig. 4. The drug concentrations listed in this table are as follows: TCB‐2 10 μmol/L, bicuculline 10 μmol/L, DNQX 20 μmol/L, ketanserin 750 nmol/L, and gabazine 10 μmol/L.